Increased Drug Resistance in Acute Lymphoblastic Leukemia Cells in Three-Dimensional High-Density Cell Cultures

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In this study, the development process of drug resistance in acute lymphoblastic leukemia cells (Jurkat, MOLT 3, and MOLT 4 cell lines) was examined in high-density cell cultures. It has been shown that in highdensity cultures of acute lymphoblastic leukemia cells resistance to the action of chemotherapeutic drugs increases comparing to the cells cultured under low-density conditions. The results obtained after investigation of the mechanism underlying increased drug resistance in acute lymphoblastic leukemia cells in high-density cell cultures showed that an increase in drug resistance in high-density cultures of cells can be mediated by a change in their proliferative activity. These findings can be applied in developing a strategy to overcome drug resistance in acute lymphoblastic leukemia cells, which depends on the density of the cell culture.

作者简介

D. Shtatnova

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences

Pushchino, Russia

M. Kobyakova

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences; Research Institute of Clinical and Experimental Lymphology – Branch of the Institute of Cytology and Genetics Siberian Branch of the Russian Academy of Sciences

Email: ritaaaaa49@gmail.com
Pushchino, Russia; Novosibirsk, Russia

Y. Lomovskaya

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences

Pushchino, Russia

E. Fetisova

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences

Pushchino, Russia

K. Krasnov

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences

Pushchino, Russia

R. Fadeev

Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences

Pushchino, Russia

参考

  1. Terwilliger T. and Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J., 7 (6), e577 (2017). doi: 10.1038/bcj.2017.53
  2. Ekpa Q. L., Akahara P. C., Anderson A. M., Adekoya O. O., Ajayi O. O., Alabi P. O., Okobi O. E., Jaiyeola O., and Ekanem M. S. A review of acute lymphocytic leukemia (ALL) in the pediatric population: evaluating current trends and changes in guidelines in the past decade. Cureus, 15 (12), e49930 (2023). doi: 10.7759/cureus.49930
  3. Inaba H. and Mullighan C. G. Pediatric acute lymphoblastic leukemia. Haematologica, 105 (11), 2524–2539 (2020). doi: 10.3324/haematol.2020.247031
  4. Ma C., Witkowski M.T., Harris J., Dolgalev I., Sreeram S., Qian W., Tong J., Chen X., Aifantis I., and Chen W. Leukemia-on-a-chip: Dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. Sci. Adv., 6, eaba5536 (2020). doi: 10.1126/sciadv.aba5536
  5. Dander E., Palmi C., D'Amico G., and Cazzaniga G. The bone marrow niche in B-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia. Int. J. Mol. Sci., 22 (9), 4426 (2021). doi: 10.3390/ijms22094426
  6. Hoffbrand A. V. and Pettit J. E. Clinical Hematology (Mosby, Incorporated, 2000), vol. 2, p. 408.
  7. Jo Y., Choi N., Kim K., Koo H. J., Choi J., and Kim H. N. Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development. Theranostics, 8 (19), 5259–5275 (2018). doi: 10.7150/thno.29098
  8. Sabelstrom H., Quigley D. A., Fenster T., Foster D. J., Fuchshuber C. A. M., Saxena S., Yuan E., Li N., Paterno F., Phillips J. J., James C. D., Norling B., Berger M. S., and Persson A. I. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Exp. Cell Res., 378 (1), 76–86 (2019). doi: 10.1016/j.yexcr.2019.03.003

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russian Academy of Sciences, 2024